

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to the course of action to be taken, you should consult your stockbroker, bank manager, solicitor, accountant or any other professional adviser immediately.

Bursa Malaysia Securities Berhad (“Bursa Securities”) has not perused the contents of this Statement prior to its issuance as it is prescribed as an exempt circular pursuant to Practice 18 of the Main Market Listing Requirements of Bursa Securities.

Bursa Securities takes no responsibility for the contents of this Statement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from, or due to your reliance upon, the whole or any part of the contents of this Statement.



HEXTAR HEALTHCARE BERHAD

[Registration No. 199601000297 (372642-U)
(Incorporated in Malaysia)]

STATEMENT TO SHAREHOLDERS

IN RELATION TO THE

**PROPOSED RENEWAL OF AUTHORITY FOR THE COMPANY TO PURCHASE OF ITS OWN
SHARES (“PROPOSED RENEWAL OF SHARE BUY-BACK AUTHORITY”)**

The above proposal will be tabled as an ordinary resolution at the Twenty-Ninth Annual General Meeting (“29th AGM”) of Hextar Healthcare Berhad (“Hexcare” or the “Company”) which will be held at The Room, Level 1, Impiana Hotel Ipoh, 18 Jalan Sultan Nazrin Shah, 30250 Ipoh, Perak, Malaysia on Thursday, 29 May 2025 at 12:00 p.m. or any adjournment thereof. This Statement is available at www.hextarhealthcare.com together with the Annual Report 2024.

A member entitled to attend and vote at the 29th AGM is entitled to appoint a proxy or proxies to attend and vote on your behalf. You must complete and deposit the Form of Proxy at the office of our Company’s Share Registrar, Aldpro Corporate Services Sdn Bhd of B-21-1, Level 21, Tower B, Northpoint Mid Valley City, No. 1, Medan Syed Putra Utara, 59200 Kuala Lumpur not less than forty-eight (48) hours before the time set for the 29th AGM or any adjournment thereof. The lodging of the Form of Proxy will not preclude you from attending and voting in person at the meeting if you are subsequently able to do so.

Last date and time for lodging the Form of Proxy : Tuesday, 27 May 2025 at 12:00 p.m.

Date and time of the 29th AGM : Thursday, 29 May 2025 at 12:00 p.m. or
at any adjournment thereof

This Share Buy-Back Statement is dated 28 April 2025

DEFINITIONS

For the purposes of this Statement, except where the context otherwise requires, the following definitions shall apply:

“Act”	: The Companies Act, 2016 and any amendments made thereto from time to time, and includes every statutory modification or any re-enactment thereof for the time being in force
“AGM”	: Annual General Meeting
“Board”	: The Board of Directors of Hexcare
“Bursa Securities”	: Bursa Malaysia Securities Berhad
“CDS”	: Central Depository System
“Code”	: Malaysia Code on Take-overs and Mergers, 2016 as amended from time to time
“Director”	: Shall have the meaning given in Section 2(1) of the Capital Markets and Services Act 2007 and includes any person who is or was within the preceding six (6) months of the date on which the terms of the transaction were agreed upon, a director or a chief executive of Hexcare or any other company which is a subsidiary of Hexcare or a holding of Hexcare
“EPS”	: Earnings per Share
“LPD”	: 2 April 2025, being the latest practicable date prior to the printing of this Statement
“Listing Requirements”	: Main Market Listing Requirements and any amendments that may be made from time to time
“Major Shareholder”	<p>: Means a person who has an interest or interests in one or more voting shares in the Company and the number or aggregate number of those shares, is:</p> <p>(a) 10% or more of the total number of voting shares in the Company; or</p> <p>(b) 5% or more of the total number of voting shares in the Company where such person is the largest shareholder of the Company.</p> <p>For the purpose of this definition, “interest” shall have the meaning of “interest in shares” given in Section 8 of the Act.</p>
“Market Day(s)”	: Means a day on which the stock market of Bursa Securities is open for trading in securities, which may include a Surprise Holiday.

DEFINITIONS (CONT'D)

“NA”	: Net assets attributable to ordinary equity holders of Hexcare .
“Proposed Share Buy-Back”	: Proposed purchase of up to ten per centum (10%) of Hexcare’s total number of issued shares.
“Proposed Renewal of Share Buy-Back Authority”	: Proposed renewal of authority for Hexcare to purchase its own ordinary shares of up to ten per centum (10%) of the total number of issued shares of Hexcare.
“RM” and “sen”	: Ringgit Malaysia and sen, respectively.
“Hexcare” or “the Company”	: Hextar Healthcare Berhad [Registration No. 199601000297 (372642-U)]
“Hexcare Group” or “Group”	: Hexcare and its subsidiaries, collectively.
“Hexcare Share(s)” or “Share(s)”	: Ordinary share(s) in Hexcare.
“Statement”	: Statement to Shareholders dated 28 April 2025 in relation to the Proposed Renewal of Share Buy-Back Authority.
“SC”	: Securities Commission Malaysia.
“Substantial Shareholder(s)”	: A person who has interest or interests in one or more voting shares in the Company and the nominal amount of that share, or aggregate of the nominal amount of those shares, is not less than 5% of the aggregate of the nominal amount of all the voting shares in the Company.
“Treasury Shares”	: Purchased Shares which are or will be retained in treasury by the Company and shall have the meaning given under Section 127(4)(b) of the Act.

Words incorporating the singular shall, where applicable, include the plural and vice versa and words incorporating the masculine gender shall, where applicable, include the feminine and neuter genders and vice versa. Reference to persons shall include a corporation, unless otherwise specified.

Any reference in this Statement to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any reference to a time of a day in this Statement shall be a reference to Malaysian time, unless otherwise specified.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK
--

TABLE OF CONTENTS

	PAGES
1. INTRODUCTION	
2. DETAILS OF THE PROPOSED RENEWAL OF SHARE BUY-BACK AUTHORITY	2-5
3. RATIONALE FOR THE PROPOSED RENEWAL OF SHARE BUY-BACK AUTHORITY	6
4. EFFECTS OF THE PROPOSED RENEWAL OF SHARE BUY-BACK AUTHORITY	6-7
5. INTEREST OF DIRECTORS, MAJOR AND/OR SUBSTANTIAL SHAREHOLDERS AND/OR PERSON CONNECTED TO THEM	8
6. APPROVAL REQUIRED	9
7. HISTORICAL SHARE PRICES	9
8. DIRECTORS' RECOMMENDATION	9
9. AGM	10
10. FURTHER INFORMATION	10
APPENDIX I – FURTHER INFORMATION	11

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK
--



HEXTAR HEALTHCARE BERHAD

[Registration No. 199601000297 (372642-U)
(Incorporated in Malaysia)]

Registered Office

B-21-1, Level 21, Tower B,
Northpoint Mid Valley City,
No. 1, Medan Syed Putra Utara,
59200 Kuala Lumpur

28 April 2025

Board of Directors: -

Mr. Liew Jee Min @ Chong Jee Min - *Independent Non-Executive Chairman*

Mr. Khoo Chin Leng - *Managing Director*

Mr. Goh Hsu-Ming - *Executive Director*

Mr. Sim Yee Fuan - *Independent Non-Executive Director*

Ms. Doris Cheng Chin Ching - *Independent Non-Executive Director*

Ms. Liew Siew Eng - *Independent Non-Executive Director*

To : The Shareholders of Hexcare

Dear Sir/Madam,

PROPOSED RENEWAL OF SHARE BUY-BACK AUTHORITY

1. INTRODUCTION

On 25 April 2025, the Board announced that the Company proposed to seek the approval of its shareholders for the Proposed Renewal of Share Buy-Back Authority at the forthcoming 29th AGM of the Company.

The purpose of this Statement is to provide you with the relevant details of the Proposed Renewal of Share Buy-Back Authority to be tabled at the forthcoming 29th AGM of the Company.

SHAREHOLDERS ARE ADVISED TO READ THE CONTENTS OF THIS STATEMENT CAREFULLY BEFORE VOTING ON THE RESOLUTION PERTAINING TO THE PROPOSED RENEWAL AT THE FORTHCOMING AGM.

<p>THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK</p>

2. DETAILS OF THE PROPOSAL RENEWAL OF SHARE BUY-BACK AUTHORITY

At the last 28th AGM held on 27 May 2024, the Company had obtained the approval of its shareholders to purchase up to ten per centum (10%) of the Company's total number of issued shares as at the point of purchase. In accordance to the Listing Requirements governing the purchase of own shares by a listed company, the aforesaid approval will be continuing in force until the conclusion of the Company's forthcoming 29th AGM which will be held on 29 May 2025.

In view of the above, the Board proposes to seek your approval for the Proposed Renewal of Share Buy-Back Authority. The Proposed Renewal of Share Buy-Back Authority shall be effective upon the passing of the ordinary resolution in the forthcoming AGM until:-

- i. the conclusion of the next AGM of the Company following the AGM at which the ordinary resolution for the Proposed Renewal of Share Buy-Back Authority was passed, at which time it shall lapse, unless the authority is renewed by a resolution passed at the next AGM; or
- ii. the expiration of the period within which the next AGM of the Company is required by any prevailing laws, rules, regulations, orders, guidelines and requirements issued by the relevant authorities including but not limited to the Listing Requirements; or
- iii. the authority is revoked or varied by ordinary resolution passed by the shareholders of the Company at a general meeting of the Company.

whichever occurs first.

2.1 Maximum number or percentage of shares to be purchased

The maximum aggregate number of Hexcare Shares which may be purchased by the Company shall not exceed ten percent (10%) of the total number of issued shares of the Company at any point in time pursuant to Paragraph 12.09 of the Listing Requirements.

As at the LPD, the maximum number of Hexcare Shares that can be purchased and/or held by the Company will be as follows:

	<u>No of Shares</u>
Total number of issued shares of Hexcare (including 91,273,100 Treasury Shares)	1,193,383,881
10% of the total number of issued shares	119,338,388
Less: Total number of treasury shares held by Hexcare	(91,273,100)
Maximum number of shares which may be purchased in respect of the Proposed Share Buy-Back	<u>28,065,288</u>

The actual number of Hexcare Shares to be purchased by the Company and the total amount of funds involved for each purchase(s) and the time of the purchase(s) will depend on inter alia, the market conditions and sentiments of the stock market, the availability of financial resources of the Company and the availability of the retained profits of the Company.

2.2 Maximum amount of funds to be allocated and source of funds

The funding for the purchase of Hexcare Shares pursuant to the Proposed Share Buy-Back may be decided by using internally generated funds and/or borrowings or a combination of both, the proportion of which will depend on the actual number of Hexcare Shares to be purchased, the price(s) of the Shares, available funds at the time of purchase(s) and other relevant cost factors.

The maximum amount allocated for such transactions shall not exceed the aggregate balance standing in the retained profits of the Company.

Based on the latest Audited Financial Statements of the Company for the financial year ended 31 December 2024, the retained losses of the Company was RM20,979,337. Notwithstanding this, the Company shall only implement the Proposed Share Buy-Back when the retained earnings of the Company is sufficient to effect the share buy-back at the material time.

As at the LPD, the Company has not determined the source of funding for the Proposed Share Buy-Back, if the Proposed Share Buy-Back is funded through internally generated funds, the Company will ensure that there is no material impact on the cash flow position of the Company. In the event the Company purchases its own shares using external borrowings, the Company will ensure its capabilities of repaying such borrowings and that such repayment will not have a material effect on its cash flow. In addition, the Board will ensure that the Company satisfies the solvency test as stated in Section 112(2) of the Act before implementing the Proposed Share Buy-Back.

2.3 Treatment of Purchased Shares

The Purchased Shares will be dealt with by the Board in accordance with Section 127 of the Act, in the following manners:

- (a) cancel the Hexcare Shares so purchased; or
- (b) retain the Hexcare Shares so purchased as Treasury Shares; or
- (c) retain part of the Hexcare Shares so purchased as Treasury Shares and cancel the remainder; or
- (d) distribute the Treasury Shares as dividends to shareholders; or
- (e) resell the Treasury Shares, or any of the Treasury Shares in accordance with the relevant rules of the Stock Exchange; or
- (f) transfer the Treasury Shares or any of the Treasury Shares for the purposes of under an employees' share scheme; or
- (g) transfer the Treasury Shares, or any of the Treasury Shares as purchase consideration; or
- (h) cancel the Treasury Shares, or any of the Treasury Shares; or
- (i) sell, transfer or otherwise use the Treasury Shares for such other purpose as the Minister may by order prescribe.

The Company must immediately announce to Bursa Securities on any purchase and/or cancel its own Shares, resale or transfer of its Treasury Shares, or cancellation of its Treasury Shares pursuant to Section 127 of the Act.

While the Purchased Shares are held as Treasury Shares, the rights attached to them in relation to voting, dividends and participation in other distribution and otherwise are suspended, and the Purchased Shares shall not be taken into account in calculating the number or percentage of shares or a class of shares in the Company for any purposes including, without limiting the generality of this provision, the provisions of any law or requirements of the Constitution of the Company or the Listing Requirements on substantial shareholding, takeovers, notices, the requisitioning of meetings, the quorum for meetings and the result of a vote on a resolution at meetings of the shareholders.

2.4 Purchase/Resale Price

Pursuant to the Listing Requirements, the Company may only purchase its own Shares at a price which is not more than fifteen percent (15%) above the weighted average market price ("WAMP") for Hexcare Shares for the five (5) Market Days immediately before the date of any purchase(s).

In the case of resale or transfer of treasury shares, the Company may only resell the treasury shares on Bursa Securities or transfer treasury shares pursuant to Section 127(7) of the Act, at:

- (a) a price which is not less than the weighted average share price of Hexcare Shares for the five (5) Market Days immediately preceding the date of the purchase: and
- (b) a discounted price of not more than five (5%) to the weighted average share price of Hexcare Shares for the five (5) Market Days immediately prior to the resale provided that:
 - (i) the resale or transfer takes place no earlier than thirty (30) days from the date of purchase; and
 - (ii) the resale or transfer price is not less than the cost of purchase of the shares being resold or transferred.

2.5 Implication of the Proposed Renewal of Share Buy-Back Authority in relation to the Code

Pursuant to the Code, a person, and any person(s) acting in concert with him ("Offeror"), will be required to make a mandatory general offer for the remaining Shares of the Company not already owned by him if his stake in the Company is increased beyond 33% but less than 50% of the voting shares of the Company and has or intend to increase his shareholdings by 2% or more in any six (6) month period. However, the Offeror may seek a waiver under the Code from the Securities Commission subject to certain conditions of the Code.

Based on the shareholdings of the Substantial Shareholders of the Company as at LPD and assuming the purchase of Hexcare's own Shares is carried out in full, the purchase of Hexcare's own Shares will trigger the implication on the Code, and the Substantial Shareholders will be obliged to extend a mandatory general offer. However, the Substantial Shareholders have represented that they have no intention of triggering the obligation to undertake a mandatory general offer. Hence, Hexcare will closely monitor their shareholdings prior to any purchase of own Shares to ensure that the obligation of the Substantial Shareholders of Hexcare pursuant to the provisions of the Code is not triggered.

2.6 Public Shareholding Spread

As at LPD, the public shareholding spread of the Company was 65%. The Company will not undertake any share buy-back if that will result in breach of Paragraph 8.02(1) of the Listing Requirements which required the Company to maintain a shareholding spread of at least 25% of its total listed shares. The Board is mindful of the shareholding spread requirement and will continue to be mindful of the requirement when making of any purchase of Hexcare Shares by the Company.

2.7 Previous Purchases, Resale, Transfer and Cancellation of Shares

The Company has not purchased, resale, transferred and/or cancelled any Treasury Shares in the previous 12 months preceding this Statement. As at the LPD, a total of 91,273,100 Shares were held as Treasury Shares.

2.8 Potential Advantages and Disadvantages of the Proposed Renewal of Share Buy-Back Authority

The potential advantages of the Proposed Renewal of Share Buy-Back Authority are as follows:

- (a) The Proposed Renewal of Share Buy-Back Authority would enable the Company to utilise its financial resources more efficiently especially where there is no immediate use. If the Hexcare Shares purchased are subsequently cancelled, this may strengthen the consolidated EPS of the Group.
- (b) The Proposed Renewal of Share Buy-Back Authority will also provide the Company with opportunities for potential gains if the Purchased Hexcare Shares which are retained as Treasury Shares are resold at prices higher than their cost of purchase.
- (c) In any event, the Treasury Shares may also be distributed as share dividends to the shareholders as a reward.

The potential disadvantages of the Proposed Renewal of Share Buy-Back Authority are as follows:

- (a) The Proposed Renewal of Share Buy-Back Authority if implemented, is expected to temporarily reduce the immediate financial resources of the Hexcare Group. However, the financial resources of the Group may recover or even increase if the Purchased Hexcare Shares are held as Treasury Shares and resold in the market at the same or higher prices.
- (b) The Proposed Renewal of Share Buy-Back Authority may also result in the Group foregoing better investment opportunities which may emerge in the future and/or any income that may be derived from other alternative uses of such funds such as deposit in interest bearing instruments.

Nevertheless, the Proposed Renewal of Share Buy-Back Authority is not expected to have any potential material disadvantages to the Company and our shareholders, as it will be implemented only after careful consideration of the financial resources of the Group and its resultant impact. The Board is mindful of the interest of the Company and our shareholders and will be prudent in respect of the above exercise.

3. RATIONALE FOR THE PROPOSED RENEWAL OF SHARE BUY-BACK AUTHORITY

The implementation of the Proposed Renewal of Share Buy-Back Authority is envisaged to benefit the Company and its shareholders as follows:

- i. the Company is able to utilise its surplus financial resources more efficiently. If implemented, this may help to stabilise the supply and demand of Hexcare Shares traded on the Stock Exchange and thereby support its fundamental value.
- ii. the EPS of Hexcare and the return on equity of the Company is expected to improve as a result of a reduced share capital base.
- iii. the Purchased Shares retained as Treasury Shares provide the Board with an option to resell the Treasury Shares at a higher price and generate capital gains for the Company.
- iv. the Purchased Shares retained as Treasury Shares can be distributed as share dividend to our shareholders as a reward.

4. EFFECTS OF THE PROPOSED RENEWAL OF SHARE BUY-BACK AUTHORITY

The effects of the Proposed Renewal of Share Buy-Back Authority on share capital, NA, working capital, earnings and shareholdings of Directors and Substantial Shareholders of the Company are set out below:

4.1 Share Capital

The effect of the Proposed Share Buy-Back on the issued share capital of the Company will depend on whether the Purchased Shares are cancelled or retained as Treasury Shares.

On the assumption that the Proposed Share Buy-Back is carried out in full and all the Hexcare Shares so acquired are subsequently cancelled, the Proposed Share Buy-Back will result in the total number of issued shares of the Company as at the LPD to be reduced as follows:

	<u>No of Shares</u>
Total number of issued shares of Hexcare (including 91,273,100 shares bought and retained as Treasury Shares)	1,193,383,881
Less: Maximum number of Hexcare Shares that may be purchased and cancelled pursuant to the Proposed Renewal (including 91,273,100 Treasury Shares held by Hexcare as at LPD)	(119,338,388)
Resultant issued share capital after cancellation of Hexcare Shares bought back	<hr/> 1,074,045,493 <hr/>

The implementation of the Proposed Renewal of Share Buy-Back Authority will not have any effect on the share capital of Hexcare Group if the Hexcare Shares purchased are retained as Treasury Shares, but the rights attaching to the Treasury Shares as to voting, dividends and participation in other distributions or otherwise will be suspended. The Act prohibits the taking into account of such shares in calculating the number of percentage of shares in the Company for a purpose whatsoever including substantial shareholdings, takeovers, notices, requisitioning of meetings, quorum for meetings and the results of votes on resolution.

4.2 NA

When the Company purchases its own Hexcare Shares, regardless of whether they are retained as Treasury Shares or subsequently cancelled, the net assets per Share of the Group will decrease if the cost per Hexcare Shares purchased exceeds the net assets per Share of the Hexcare Group at the relevant point in time. However, if the cost per Hexcare Share purchased is below the net assets per Share of the Group at the relevant point in time, the net assets per Hexcare Share of the Group will increase.

In the case where the Hexcare Shares purchased are treated as Treasury Shares and subsequently resold, the net assets per Hexcare Share upon the resale will increase if the Company realises a gain from the resale and vice-versa. If the Treasury Shares are distributed as share dividends, the net assets of the Group will decrease by the cost of the Treasury Shares at the point of purchase.

4.3 Working Capital, Cash Flow and Gearing

The share purchased will result in an outflow of cash and thereby reduce working capital of the Group, the quantum of which is dependent on the purchase prices and number of the Purchased Shares as well as the funding cost, if any. However, the working capital and cash flow of the Company will increase upon reselling of the Purchased Shares which are retained as treasury shares. Again, the quantum of the increase in working capital and cash flow will depend on the actual selling price of treasury shares and the number of treasury shares resold.

4.4 Dividends

Barring unforeseen circumstances, the Proposed Renewal of Share Buy-Back Authority is not expected to have any impact on the policy of the Board in recommending dividends, if any to shareholders of Hexcare. However, any future dividend to be declared and paid will depend on, amongst others, the actual results of the Hexcare Group, its cash reserves, capital commitment and future funding requirements.

The Board may have the option to distribute future dividends in the form of treasury shares purchased pursuant to the Proposed Renewal of Share Buy-Back Authority.

4.5. Directors' and Substantial Shareholders' Shareholdings

The Based on the Registers of Directors' Shareholdings and Substantial Shareholders' Shareholdings as at LPD and assuming that the Proposed Share Buy-Back is implemented up to the maximum of 10% of the total number of issued shares of the Company and that the Shares are bought from the shareholders other than the Directors and Substantial Shareholders of Hexcare, the effect of the Proposed Share Buy-Back on the shareholdings of the Directors and Substantial Shareholders of Hexcare are set out below:

Directors	No of Shares held as at LPD*			After the Proposed Share Buy-Back#		
	Direct Interest	Indirect Interest		Direct Interest	Indirect Interest	
	No of Shares	%	No of Shares	%	No of Shares	%
Liew Jee Min @ Chong Jee Min	-	-	-	-	-	-
Khoo Chin Leng	58,486	0.005	6,396 ⁽¹⁾	0.001 ⁽¹⁾	58,486	0.005
Goh Hsu-Ming	-	-	-	-	-	-
Sim Yee Fuan	-	-	-	-	-	-
Doris Cheng Chin Ching	-	-	-	-	-	-
Lim Siew Eng	-	-	-	-	-	-
Substantial Shareholders						
Hextar Rubber Sdn. Bhd.	252,171,566	22.881	-	-	252,171,566	23.479
Dato' Ong Choo Meng	-	-	252,171,566 ⁽²⁾	22.881 ⁽²⁾	-	23.479 ⁽²⁾
Revongen Corporation Sdn. Bhd.	132,467,918	12.019	-	-	132,467,918	12.334
					-	-

Notes:

* Calculated based on the total number of shares issued (less Treasury Shares of 91,273,100) of 1,102,110,781 Shares at LPD.

Calculated based on the total number of shares (after adjusting for 119,338,388 Shares Buy-Back pursuant to the Proposed Renewal of Share Buy-Back Authority) of 1,074,045,493 Shares at LPD.

⁽¹⁾ Deemed Interest by virtue of his spouse's interest pursuant to Section 59(11)(c) of the Act.

⁽²⁾ Deemed Interest by virtue of his shareholding in Hextar Rubber Sdn Bhd pursuant to Section 8 of the Act.

5. APPROVAL REQUIRED

The Proposed Renewal of Share Buy-Back Authority is subject to the approval of our shareholders at the forthcoming 29th AGM to be convened. Save for the approval of the shareholders of Hexcare, there is no other approvals required for the Proposed Renewal of Share Buy-Back Authority .

6. INTEREST OF DIRECTORS, MAJOR AND/OR SUBSTANTIAL SHAREHOLDERS AND/OR PERSON CONNECTED TO THEM

None of the Directors, major and/or Substantial Shareholders and/or persons connected to them, has any interest, direct or indirect, in the Proposed Share Buy-Back or the subsequent resale of the Treasury Shares, if any.

7. HISTORICAL SHARE PRICES

The monthly highest and lowest price of Hexcare Shares as traded in Bursa Securities for the past twelve (12) months from April 2024 to March 2025 are as follows:-

Month	Highest (RM)	Lowest (RM)
2024		
April	0.220	0.195
May	0.275	0.205
June	0.250	0.220
Jul	0.290	0.220
Aug	0.255	0.185
Sept	0.215	0.180
Oct	0.190	0.180
Nov	0.200	0.170
Dec	0.190	0.165

Month	Highest (RM)	Lowest (RM)
2025		
Jan	0.195	0.165
Feb	0.185	0.145
March	0.155	0.130

The last transacted price of Hexcare Shares on 2 April 2025, being the LPD, was RM0.135 per share.

(Source :www.shareinvestor.com)

8. DIRECTORS' RECOMMENDATION

The Board, having considered the Proposed Renewal, is of the view that the Proposed Renewal is in the best interest of the Company. Accordingly, the Board recommends that the shareholders of Hexcare vote in favour of the ordinary resolution pertaining to the Proposed Renewal to be tabled at the 29th AGM of the Company.

9. AGM

The ordinary resolution pertaining to the Proposed Renewal of Share Buy-Back Authority is stated in the Notice of 29th AGM in the Company's Annual Report 2024. The 29th AGM of the Company will be held at The Room, Level 1, Impiana Hotel Ipoh, 18 Jalan Sultan Nazrin Shah, 30250 Ipoh, Perak, Malaysia on Thursday, 29 May 2025 at 12:00 p.m. or any adjournment thereof for the purpose of consideration and, if thought fit, passing the resolutions relating to the Proposed Renewal of Share Buy-Back Authority to give effect to the proposal.

A member entitled to attend and vote at the 29th AGM is entitled to appoint a proxy or proxies to attend and vote on your behalf. You must complete and deposit the Form of Proxy at the office of our Company's Share Registrar, Aldpro Corporate Services Sdn Bhd of B-21-1, Level 21, Tower B, Northpoint Mid Valley City, No. 1, Medan Syed Putra Utara, 59200 Kuala Lumpur not less than forty-eight (48) hours before the time set for the 29th AGM or any adjournment thereof. The lodging of the Form of Proxy will not preclude you from attending and voting in person at the meeting if you are subsequently able to do so.

10. FURTHER INFORMATION

Shareholders are advised to refer to Appendix for further information.

Yours faithfully,
For and on behalf of the Board of
HEXTAR HEALTHCARE BERHAD

KHOO CHIN LENG
Managing Director

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK
--

APPENDIX I – FURTHER INFORMATION

1. DIRECTORS' RESPONSIBILITY STATEMENT

This Statement has been seen and approved by the Directors of Hexcare who individually and collectively accept full responsibility for the accuracy of the information contained in this Statement and confirm that after making all reasonable enquiries and to the best of their knowledge and belief, there are no other facts the omission of which would make any statement herein misleading or incorrect.

2. MATERIAL CONTRACTS

There are no material contracts (not being contracts entered into in the ordinary course of business) which have been entered into by the Company or its subsidiary companies within two (2) years preceding the date of this Statement.

3. MATERIAL LITIGATION

Neither Hexcare nor its subsidiary companies are engaged in any material litigation, claim or arbitration, either as plaintiff or defendant, and the Directors of Hexcare have no knowledge of any proceedings, pending or threatened or of any fact likely to give rise to any proceedings which might materially and adversely affect the position or business of Hexcare and its subsidiary companies.

4. DOCUMENTS AVAILABLE FOR INSPECTION

Copies of the following documents are available for inspection by the shareholders of Hexcare at the Registered Office of Hexcare at B-21-1, Level 21, Tower B, Northpoint Mid Valley City, No. 1, Medan Syed Putra Utara, 59200 Kuala Lumpur during normal office hours between Monday and Friday (except public holidays) from the date of this Statement up to and including the date of the 29th AGM:

- (i) The Constitution of Hexcare;
- (ii) The audited consolidated financial statements of Hexcare Group for the past two (2) financial years ended 31 December 2023 and 2024 respectively and latest unaudited results since the last audited financial statements.